Oaktree Acquisition Corp. III Life Sciences OACC
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Report as our initial business combination. To date, our efforts have been limited to organizational activities, activities related to our initial public offering and our search for an initial business combination. We have not selected any specific business combination target yet. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Operating income | -$1.2M | — |
| Net income | $7.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | $1.4M | $1.4M |
| Total current assets | $1.5M | $1.6M |
| Total assets | $203.1M | $195.3M |
| Accounts payable | $502.0K | $535.5K |
| Total current liabilities | $1.3M | $727.3K |
| Total liabilities | $8.3M | $7.7M |
| Retained earnings | -$6.8M | -$6.1M |
| Total equity | -$6.8M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | -$422.1K | — |
| Investing cash flow | $500.0K | — |
| Financing cash flow | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-126536.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Net income | — | $7.3M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Annual report filed Form 10-K
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $649.1M | — | — |
| IACO | Idea Acquisition Corp. | $437.9M | — | — |
| KRAQ | KRAKacquisition Corp | $430.8M | — | — |
| TACO | Berto Acquisition Corp. | $393.2M | 36.1x | — |
| ALDF | Aldel Financial II Inc. | $328.0M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $290.3M | — | — |
| FGII | FG Imperii Acquisition Corp. | $290.3M | — | — |
| SOUL | Soulpower Acquisition Corp. | $269.3M | — | — |